What is Wedbush’s Forecast for ASND Q3 Earnings?

Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Wedbush issued their Q3 2024 earnings estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the biotechnology company will post earnings per share of ($1.98) for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.24) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($1.71) EPS, FY2024 earnings at ($8.27) EPS, Q1 2025 earnings at ($1.86) EPS, Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at $0.64 EPS, FY2027 earnings at $5.19 EPS and FY2028 earnings at $10.99 EPS.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million.

A number of other equities research analysts have also weighed in on the stock. Oppenheimer reissued an “outperform” rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. reduced their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. Finally, Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.92.

Ascendis Pharma A/S Trading Down 1.8 %

Shares of ASND stock opened at $124.33 on Thursday. The business’s 50-day moving average price is $132.26 and its 200-day moving average price is $133.17. Ascendis Pharma A/S has a 12 month low of $86.54 and a 12 month high of $161.00. The firm has a market capitalization of $7.54 billion, a price-to-earnings ratio of -13.35 and a beta of 0.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ASND. Price T Rowe Associates Inc. MD lifted its holdings in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Fred Alger Management LLC lifted its position in Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after acquiring an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP boosted its stake in Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.